BioMarin's Gene Therapy for Adults with Severe Hemophilia A, ROCTAVIAN™ (valoctocogene roxaparvovec), Assessed to Provide Substantial Cost Savings Per Patient in a Preliminary Independent Report
Provided By PR Newswire
Last update: Sep 15, 2022
Institute for Clinical and Economic Review (ICER) Base-Case Model Report Results in $4 Million Savings Versus Emicizumab Prophylaxis Per Patient Over a Lifetime
Read more at prnewswire.com58.23
+0.13 (+0.22%)
Find more stocks in the Stock Screener
BMRN Latest News and Analysis
19 days ago - ChartmillBIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) – An Undervalued Biotech Stock With Strong FundamentalsBIOMARIN PHARMACEUTICAL (NASDAQ:BMRN) is an undervalued biotech stock with strong profitability, financial health, and growth potential, making it a candidate for value investors.
